Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01162681 · ClinicalTrials.gov registry record · Phase 2
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 547
- Enrollment target
NCT01162681 is a Phase 2 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 547 participants.
The verdict
NCT01162681, a Phase 2 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 547 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease
Interventions
- OTHER Placebo Comparator
- DRUG A-623
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01162681
The ClinicalTrials.gov registry entry for NCT01162681 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 547 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT01162681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01162681 about?
NCT01162681 is a clinical study titled "PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease
What is the current status of trial NCT01162681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 547 participants. The study started on 2010-07. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01162681?
The interventions under investigation include: Placebo Comparator (OTHER), A-623 (DRUG).
Who is sponsoring clinical trial NCT01162681?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.